Cimeio Therapeutics
Developing Shielded-Cell & Immunotherapy Pairs for patients with debilitating and life-threatening diseases
Cimeio Therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research carried out by Professor Lukas Jeker – one of the co-founders of the company and SVP Gene Editing – and his group.
Cimeio is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Its proprietary technology platform is based on the discovery of variants, which when inserted into cells allow them to preserve function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Cimeio was initially supported by BaseLaunch and later built out of Ridgeline Discovery, the Versant Ventures Discovery Engine in Basel and on April 13th 2022 announced a USD 50 million Series A financing by Versant.
”Without BaseLaunch Cimeio would not have been born. The funding was instrumental to cover key needs in our earliest life but as a scientist at heart getting the BaseLaunch team’s business advice was equally important. The team’s exceptional domain expertise, integrity and their tremendous flexibility and “can do” attitude impressed me. I can only encourage anyone thinking about forming a biotech venture to work with the team at BaseLaunch.
Prof. Dr. Lukas JekerFounder, SVP gene editing & Professor at the University of Basel
